0%
Labrynix PGx Reporting

White-label PGx reporting — 700+ medications.

Branded, evidence-informed pharmacogenomics reports your lab sells under its own name — drafted by our lab-trained AI, reviewed and signed out by your qualified staff, and informed by CPIC, FDA labeling, DPWG, and PharmGKB. Run it standalone with the LIS you already have, or on the Labrynix platform. Built by the team behind a CLIA-certified genetic lab.

Book a Demo →View a sample report
Why labs buy it on its own

Add PGx reporting without a migration.

PGx Reporting is one of Labrynix's biggest sellers as a standalone product. Labs keep the LIS they already run, send genotype data in, and get modern, white-label PGx reports back — reviewed and signed out by their own staff.

No rip-and-replace, no six-month implementation before the first report. The reporting layer is the product — and it's the same one we run PGx on inside a CLIA-certified lab.

◆

Standalone

Keep your LIS. Connect via API, HL7v2, FHIR, or secure upload.

◆

White-label

Your logo, colors, layout, disclaimers, and delivery — your product.

◆

Lab-signed

AI drafts; your qualified staff review, approve, and sign out.

Two ways to run it

Standalone today. Platform when you're ready.

Standalone — keep your LIS

Your existing system sends orders and genotype data via API, HL7v2, FHIR, or secure upload. Labrynix translates phenotypes, drafts the report, routes it through your review and electronic sign-out, and returns a branded PGx report — as a PDF, through your portal, or back into your LIS/EHR.

On the Labrynix platform

Run the whole PGx operation in one place — orders, accessioning, sample tracking, genotyping QC, reporting, provider and patient portals, and billing visibility — with PGx Reporting native to the workflow on Labrynix LIMS.

See inside the report

A PGx report providers actually read.

Traffic-light guidance, evidence-graded calls, and phenotype summaries — branded as your lab, drafted by AI, signed out by your team. Not a wall of tables.

Your Labwhite-label
Comprehensive Pharmacogenomic Report AI-drafted · Lab-signed
Patient SampleSpecimen SalivaAccession 4123·0611·7027Panel 700+ medications
Phenotype summary
CYP2D6*2/*2Normal metabolizer
CYP2C19*1/*17Rapid metabolizer
CYP2C9*1/*1Normal metabolizer
SLCO1B1*1/*5Decreased function
VKORC1−1639 G>AHigh sensitivity
CYP3A5*3/*3Non-expresser
Medication response
MedicationGenePhenotypeGuidanceEv.
CodeineCYP2D6NormalStandard dosing1A
SimvastatinSLCO1B1DecreasedHigh myopathy risk1A
ClopidogrelCYP2C19RapidStandard dosing1A
WarfarinVKORC1 · CYP2C9SensitiveDose with caution1A
CitalopramCYP2C19RapidMay reduce effect1A
TramadolCYP2D6NormalStandard dosing1B
TamoxifenCYP2D6NormalStandard dosing3
CPICFDA labelingDPWGPharmGKB
Reviewed & electronically signed out · Laboratory Director

Illustrative sample · synthetic genotype data · your branding and rules.

Your brand, cover to footer

Logo, colors, contact details, and disclaimers — the report reads as your lab's product, because it is.

Traffic-light guidance

Standard, monitor, or caution — at a glance — so a clinician sees the answer before reading the detail.

Phenotype & diplotype detail

Star alleles, diplotypes, and predicted metabolizer status — including deep CYP2D6 and copy-number calls where your assay supports them.

Evidence on every call

Each gene-drug association carries its CPIC/PharmGKB evidence level and a traceable source — no unsupported assertions.

See the full sample report →
Coverage

700+ medications across 12 clinical specialties.

One report spans the prescribing areas providers actually ask about — from cardiology and psychiatry to oncology and the over-the-counter drugs most PGx panels skip.

01

Pain Management

Opioids, NSAIDs, anti-gout, antirheumatics

CYP2D6OPRM1CYP2C9
02

Cardiovascular

Antiarrhythmics, antihypertensives, statins, anticoagulants

CYP2C9VKORC1SLCO1B1
03

Internal Medicine

PPIs, antiemetics, respiratory, diabetes

CYP2C19CYP2D6
04

Psychiatry

Antidepressants (SSRIs / SNRIs), antipsychotics

CYP2D6CYP2C19HTR2A
05

Neurology

ADHD, epilepsy, sedatives, Alzheimer's & Parkinson's

CYP2D6CYP2C9HLA-A
06

Infectology

Antibiotics, antifungals, antiretrovirals

CYP2B6G6PD
07

Oncology & Hematology

Antineoplastics & targeted therapies

DPYDTPMTUGT1A1
08

Organ Transplant

Immunosuppressants & immunomodulation

CYP3A5TPMT
09

Anesthesiology

Anesthetics & muscle relaxants

CYP2D6RYR1BCHE
10

Urology

Incontinence, erectile dysfunction, BPH

CYP2D6CYP3A5
11

Endocrinology

Contraceptives, thyroid, glucocorticoids

CYP2C9CYP3A4
12

Recreational

Alcohol, cannabinoids, benzodiazepines

CYP2C9ADH1B
The panel

The pharmacogenes that drive the calls.

From the high-impact CYP enzymes to transporters, thiopurine genes, and HLA risk alleles — including deep CYP2D6 star-allele and copy-number calling where your assay supports it.

CYP2D640+ alleles + CNV
CYP2C19*1–*17
CYP2C9*1–*15
SLCO1B1*5 / *15
VKORC1−1639 G>A
CYP3A5expresser status
DPYD
TPMT
CYP2B6
CYP3A4
NUDT15
UGT1A1
OPRM1
ABCB1
HLA-A / B
G6PD
COMT
F2 / F5

Final panel content follows your validated assay and interpretation rules — Labrynix structures and reports what your lab calls.

Evidence & updates

Grounded in the sources providers trust.

No single source is enough — FDA labeling specifies an action for only some drugs, and FDA and CPIC don't always agree — so Labrynix draws on all four and reconciles them under your lab's validated rules. Reference content is versioned: updates are deliberate, never silent, and your team always knows which version a signed report referenced.

CPIC

CPIC-informed gene-drug guideline references and recommendation structures where applicable — the consortium guidance providers ask about by name.

FDA PGx labeling

Report sections can reference FDA pharmacogenomic biomarker and labeling information where applicable, including FDA-recognized gene-drug associations.

DPWG

Support for Dutch Pharmacogenetics Working Group guideline-informed content — widely used alongside CPIC for international coverage.

PharmGKB

Reporting content informed by PharmGKB gene-drug annotations, clinical annotations, and drug-label resources where appropriate.

Graded, not guessed

Every association carries its level of evidence.

Reports surface the strength behind each gene-drug call — from CPIC-guideline-backed (1A) to preliminary (4) — so clinicians weigh guidance with the confidence it actually deserves.

1A

Guideline-backed

In a CPIC or medical-society PGx guideline, or implemented at a major health system.

1B

Strong evidence

Preponderance of evidence, replicated across more than one cohort with a significant effect.

2A

VIP pharmacogene

Variant within a Very Important Pharmacogene (PharmGKB) — functional significance likely.

2B

Moderate

Moderate, replicated evidence; some studies may not reach significance.

3

Emerging

A single significant study, or multiple studies lacking a clear association.

4

Preliminary

Case report, non-significant study, or in-vitro / functional evidence only.

No black box

Every call shows its work.

The fastest way to lose a lab director's trust is an interpretation they can't explain. Opaque, proprietary PGx engines have been shown to diverge from CPIC guidance — and a recommendation you can't trace is one a provider can't defend. Labrynix is built the other way.

Source-cited, not asserted

Every gene-drug call traces to its CPIC, FDA labeling, DPWG, or PharmGKB basis, with version notes — visible to your team and the providers you serve.

CPIC-standard terminology

Diplotype-to-phenotype translation expressed in standardized CPIC phenotype terms, so reports read consistently and match the guidance providers already know.

Your rules, your sign-out

Interpretation runs on your lab's validated, approved rules, and a qualified staff member reviews and electronically signs out every report. AI never makes the clinical call.

Structured to the standard

Reports follow the ACMG clinical pharmacogenomics technical standard — nomenclature, testing, interpretation, reporting — and Labrynix supports the documentation your CLIA/CAP validation and MolDX submissions need.

How it works

Genotype in. Signed report out.

Step 01

Data in

Orders and genotype results from your assay — array, qPCR, or NGS — arrive via API, HL7v2, FHIR, or secure upload. No LIS migration required.

Step 02

Phenotype translation

Validated, versioned rules map star alleles and diplotypes to predicted metabolizer phenotypes — the same inputs always produce the same call.

Step 03

AI-assisted draft

Our lab-trained AI layer drafts medication-gene sections, phenotype summaries, and provider language inside your approved templates.

Step 04

Review & sign-out

Your qualified staff review, edit, approve, and electronically sign out every report. AI never releases a report on its own.

Step 05

Branded delivery

Signed reports go out as your lab's: PDF, secure provider and patient portals, or straight back into your LIS/EHR via HL7 and FHIR.

Step 06

Billing support

MolDX DEX Z-code, prior-authorization, and medical-necessity documentation tracked per order — what payers increasingly require to pay PGx claims.

AI drafts. Your lab signs out.

Labrynix PGx Reporting supports report creation, phenotype translation, source organization, and delivery workflows. Qualified laboratory staff perform validation, interpretation, final approval, and sign-out — AI assists the review, it never replaces it, and it never makes the clinical decision.

Judge the output

See a real report, not a brochure.

View a branded sample PGx report — synthetic data, lab-signed-out, in exactly the house style your lab's reports would follow.

See the sample report →
Who runs on it

Built for labs that sell PGx testing.

Genetic testing labs

Add a PGx line to your menu without re-platforming — reporting is the only new piece you need.

Reference & molecular labs

White-label PGx reporting at volume, standardized across provider accounts and delivery channels.

Dedicated PGx labs

Run the full PGx workflow — accessioning to billing — with reporting native to the platform.

Explore solutions by lab type →
Go deeper

Compare, verify, then book.

See

A real sample report

Branded, AI-assisted, lab-signed-out — preview it free.

View the sample →
Compare

vs. Translational Software

How Labrynix compares to a dedicated PGx interpretation vendor.

See the comparison →
Learn

The Buyer's Guide

Questions to ask any PGx reporting vendor — including us.

Get the guide →
FAQ

Questions,
answered.

Yes — that is the point of the standalone product. Your existing LIS or workflow sends orders and genotype data via API, HL7v2, FHIR, or secure upload, and Labrynix returns branded PGx reports routed through your review and electronic sign-out. Many labs start standalone and adopt the wider platform later.
Yes. Logo, colors, layout, sections, headers, footers, disclaimers, and contact details are your lab's — the report reads as your product, because it is. Labrynix is the engine behind it.
Prescribing guidance spans 700+ medications — FDA-approved and over-the-counter — across cardiology, psychiatry, diabetes, pain management, and more, informed by CPIC guideline content, FDA pharmacogenomic labeling, DPWG, and PharmGKB annotations, applied under your lab's validated interpretation rules.
No. AI assists: it maps genotype to predicted phenotype, drafts summaries, and organizes source references. Validation, interpretation, approval, and final sign-out remain with your qualified laboratory staff. AI never makes the clinical decision.
Reference content is versioned and updates are applied deliberately under your lab's review and approved rules — nothing changes silently underneath a signed report, and your team always knows which version a report referenced.
Yes — that is the point. Every gene-drug call traces to its CPIC, FDA labeling, DPWG, or PharmGKB basis with version notes, expressed in standardized phenotype terminology, and is signed out by your qualified staff. Nothing is a black box: you, and the providers you serve, can see the basis for every recommendation.
Reports are structured to the ACMG clinical pharmacogenomics technical standard — nomenclature, testing, interpretation, and reporting. Because the FDA's LDT rule was vacated in 2025, CLIA is again the operative framework, and Labrynix supports the documentation your CLIA/CAP validation and MolDX submissions require, with full step traceability.
Drafts assemble in minutes once genotype data and your validated rules are in place. Release timing is governed by your lab's review and sign-out — the part that should never be rushed.
PGx billing increasingly hinges on MolDX DEX Z-codes, prior authorization, and medical-necessity documentation. Labrynix tracks that documentation per order, and Labrynix Billing carries claim-stage visibility through to payment.
Let's build the future of labs

Add PGx reporting without the migration.

Book a Demo →View a sample report

700+ medications · CPIC / FDA / DPWG / PharmGKB · White-label · Lab-signed · API / HL7 / FHIR